The potential of moving the combination to the earlier MIBC setting significantly increases the Padcev market.

ICH gives CGT developers a regulatory framework that finally matches the speed and flexibility their groundbreaking therapies ...

HPAPI manufacturing requires the highest safety and containment standards. With geopolitical tensions threatening critical ...

Nearly two dozen antibody drug conjugates (ADCs) have now been approved worldwide and revenues were already well into the ...

The latest in a trend of companies stepping back from cell and gene therapies amid regulatory uncertainty and manufacturing ...

Novo Nordisk will hold a meeting to elect new board members following a disagreement between the board and its majority shareholder.

The results strengthen Jiangsu Hengrui’s dominance in the Chinese HCC market, showing potential for camrelizumab and ...

Ventus has entered a multi-year partnership with Roche’s Genentech for the discovery and optimisation of new small-molecule ...

Health Canada has granted conditional approval for Gilead Sciences’ Lyvdelzi for PBC patients who have difficulty with ...